ASCO 2018 News

ASCO 2018 News

Episodes

Specialty:

All

Year:

All

EP. 1: OncLive News Network On Location: In Chicago Friday, June 1

June 2nd 2018

EP. 2: OncLive News Network On Location: In Chicago Saturday, June 2

June 2nd 2018

EP. 3: OncLive News Network On Location: In Chicago Sunday, June 3

June 2nd 2018

EP. 4: OncLive News Network On Location: In Chicago Monday, June 4

June 2nd 2018

EP. 5: Practice Changes for Use of Immunotherapy in NSCLC

June 2nd 2018

EP. 6: ASCO 2018: Dr. Borghaei Highlights Immunotherapy Findings in Lung Cancer

June 2nd 2018

EP. 7: ASCO 2018: Dr. Esteva Highlights CDK4/6 Inhibitors and More in Breast Cancer

June 2nd 2018

EP. 8: ASCO 2018: Dr. Burris Highlights TAILORx and More in Breast Cancer

June 2nd 2018

EP. 9: ASCO 2018: Dr. Lonial Highlights CAR T-Cell Therapy and More in Myeloma

June 2nd 2018

EP. 10: ASCO 2018: Dr. Weber Highlights Exciting Abstracts in Melanoma

June 2nd 2018

EP. 11: ASCO 2018: Dr. Coleman Shares Insight on Ongoing Research in Ovarian Cancer

June 2nd 2018

EP. 12: ASCO 2018: Dr. Bekaii-Saab Highlights Pancreatic Cancer Abstracts

June 2nd 2018

EP. 13: ASCO 2018: Dr. Birrer on Practice-Changing Ovarian Cancer Studies

June 2nd 2018

EP. 14: ASCO 2018: Dr. Westin Sheds Light on PARP Inhibitor Abstracts in Ovarian Cancer

June 2nd 2018

EP. 15: KEYNOTE Trial Data: Pembrolizumab's Role in NSCLC

June 2nd 2018

EP. 16: Actual Use of Pembrolizumab and Chemotherapy in NSCLC

June 2nd 2018

EP. 17: CheckMate-227: Testing Ipilimumab/Nivolumab in NSCLC

June 2nd 2018

EP. 18: IMPower150: Implications for the Treatment of NSCLC

June 2nd 2018

EP. 19: Important Data in the Squamous NSCLC Population

June 2nd 2018

EP. 20: Impact of Data on the Real-Life Treatment of NSCLC

June 2nd 2018

EP. 21: Tumor Mutational Burden in NSCLC: Should it be Routine?

June 2nd 2018

EP. 22: Optimizing Immunotherapy in the NSCLC Treatment Paradigm

June 2nd 2018

EP. 23: Using Immunotherapy Beyond Progression in NSCLC

June 2nd 2018

EP. 24: Practice Changes for Use of Immunotherapy in NSCLC: Q&A

June 2nd 2018

Trending on OncLive

Five Under 5: Top Oncology Videos for the Week of 8/31/26

FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer

Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC

B7-H4–Targeted ADCs Signal a New Frontier for Platinum-Resistant Ovarian and Endometrial Cancer

The OncFive: Top Oncology Articles for the Week of 8/30